REUN
Reunion Neuroscience Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. biohaven obtained licenses from yale university school of medicine and massachusetts general hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. the mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. the company’s first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at yale university who discovered the therapeutic potential of glutamate modulation in anxiety and depression. team members have designed and executed successful development programs t
Market Cap: 13.1 Million
Primary Exchange: NASDAQ
Website: biohavenpharma.com
Shares Outstanding: 11.7 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.010543835100223923
Sector: Health Care and Social Assistance
Industry: Outpatient Mental Health and Substance Abuse Centers
Ethical Flags
Longest drawdown: 65 trading days
From: 2023-02-27 To: 2023-05-31
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|